Pfizer indicates "there is a regulatory pathway forward"
Given the years of delay, additional cost incurred to bring the program to this point and development work left in the program, there will be much to consider,” Pfizer said in the letter dated May 9.
Nonetheless, “there is a regulatory pathway forward” for Remoxy, Pfizer said, citing the FDA’s comments after a March 28 hearing. Pfizer’s Remoxy team will recommend to management that it endorse the program, Alan Litwack, Pfizer’s vice president for global commercial development, said in the letter. There isn’t “an exact time frame” on when a decision will be made.
This is NOT the end of the story. Zero debt, 10's of millions of dollars in the bank and several promising drugs in the pipeline. I bought in big time on Friday when the share price dropped so much. It was like stealing money from a baby. Beats buying overpriced big company stocks. The cost for operations is minimal and I have lot's of time. If 1/2 of the current drugs in the pipeline work out the pps could easily hit $30 to $40 per share over the next few years (based on income potential).